Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers.

Prostatic Neoplasms / pathology Male Humans Biomarkers, Tumor Syndecan-1 / analysis Adaptor Proteins, Vesicular Transport Adaptor Proteins, Signal Transducing

Journal

Scientific data
ISSN: 2052-4463
Titre abrégé: Sci Data
Pays: England
ID NLM: 101640192

Informations de publication

Date de publication:
08 Aug 2024
Historique:
received: 31 01 2024
accepted: 26 07 2024
medline: 9 8 2024
pubmed: 9 8 2024
entrez: 8 8 2024
Statut: epublish

Résumé

The diagnosis of prostate cancer using histopathology is reliant on the accurate interpretation of prostate tissue sections. Current standards rely on the assessment of Haematoxylin and Eosin (H&E) staining, which can be difficult to interpret and introduce inter-observer variability. Here, we present a digital pathology atlas and online resource of prostate cancer tissue micrographs for both H&E and the reinterpretation of samples using a novel set of three biomarkers as an interactive tool, where clinicians and scientists can explore high resolution histopathology from various case studies. The digital pathology prostate cancer atlas when used in conjunction with the biomarkers, will assist pathologists to accurately grade prostate cancer tissue samples.

Identifiants

DOI: 10.1038/s41597-024-03696-0 PMID: 39117701
pubmed: 39117701
doi: 10.1038/s41597-024-03696-0
pii: 10.1038/s41597-024-03696-0
doi:

Substances chimiques

Biomarkers, Tumor 0
Syndecan-1 0
Adaptor Proteins, Vesicular Transport 0
sortilin Z020Y8WIJ4
Adaptor Proteins, Signal Transducing 0

Types de publication

Journal Article Dataset

Langues

eng

Sous-ensembles de citation

IM

Pagination

852

Subventions

Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : GNT1092904

Informations de copyright

© 2024. The Author(s).

Références

World Health Organisation. at www.who.int (2023).
Gleason, D. F. Classification of prostatic carcinomas. Cancer Chemother. Reports 50, 125–8 (1966).
Samaratunga, H. et al. The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology 47, 515–519 (2015).
doi: 10.1097/PAT.0000000000000315 pubmed: 26325670
Gleason, D. F. & Mellinger, G. T. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging. J. Urol. 111, 58–64 (1974).
doi: 10.1016/S0022-5347(17)59889-4 pubmed: 4813554
Epstein, J. I. et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 40, 244–252 (2016).
doi: 10.1097/PAS.0000000000000530 pubmed: 26492179
Epstein, J. I., Allsbrook, W. C., Amin, M. B. & Egevad, L. L. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 29, 1228–1242 (2005).
doi: 10.1097/01.pas.0000173646.99337.b1 pubmed: 16096414
van Leenders, G. J. L. H. et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 44, e87–e99 (2020).
doi: 10.1097/PAS.0000000000001497 pubmed: 32459716 pmcid: 7382533
Srigley, J. R. et al. Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. Pathology 51, 463–473 (2019).
doi: 10.1016/j.pathol.2019.05.001 pubmed: 31279442
Egevad, L. et al. Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Arch. 477, 777–786 (2020).
doi: 10.1007/s00428-020-02858-w pubmed: 32542445 pmcid: 7683442
Hassan, O. & Matoso, A. Clinical significance of subtypes of Gleason pattern 4 prostate cancer. Transl. Androl. Urol. 7, S477–S483 (2018).
doi: 10.21037/tau.2018.02.06 pubmed: 30363452 pmcid: 6178320
Flood, T. A. & Schieda, N. Beyond the Gleason score: the prognostic significance of prostate cancer subtypes. Transl. Androl. Urol. 7, S260–S261 (2018).
doi: 10.21037/tau.2018.04.01 pubmed: 29932176 pmcid: 5989107
Goodman, M. et al. Frequency and determinants of disagreement and error in gleason scores: A population-based study of prostate cancer. Prostate 72, 1389–1398 (2012).
doi: 10.1002/pros.22484 pubmed: 22228120 pmcid: 3339279
Martini, C. et al. Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer. Pathology 55, 40–51 (2023).
doi: 10.1016/j.pathol.2022.08.001 pubmed: 36089417
Logan, J. M. et al. Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1. Cancers (Basel). 15, 3215 (2023).
doi: 10.3390/cancers15123215 pubmed: 37370825 pmcid: 10296524
Sorvina, A. et al. Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread. Pathology, https://doi.org/10.1016/j.pathol.2023.05.004 (2023).
Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading. at https://newsroom.questdiagnostics.com/2023-07-13-Quest-Diagnostics-Launches-Novel-Prostate-Cancer-Test-Aimed-at-Improving-Diagnosis-and-Grading (2023).
Srigley, J. R. Benign mimickers of prostatic adenocarcinoma. Mod. Pathol. 17, 328–348 (2004).
doi: 10.1038/modpathol.3800055 pubmed: 14976539
Egevad, L. et al. Benign mimics of prostate cancer. Pathology 53, 26–35 (2021).
doi: 10.1016/j.pathol.2020.08.006 pubmed: 33070957
Johnson, I. R. D. et al. Endosomal gene expression: a new indicator for prostate cancer patient prognosis? Oncotarget 6, 37919–37929 (2015).
doi: 10.18632/oncotarget.6114 pubmed: 26473288 pmcid: 4741974
Johnson, I. R., Parkinson-Lawrence, E. J., Butler, L. M. & Brooks, D. A. Prostate cell lines as models for biomarker discovery: Performance of current markers and the search for new biomarkers. Prostate 74, 547–560 (2014).
doi: 10.1002/pros.22777 pubmed: 24435746
Johnson, I. R. D. et al. Altered endosome biogenesis in prostate cancer has biomarker potential. Mol. Cancer Res. 12, 1851–1862 (2014).
doi: 10.1158/1541-7786.MCR-14-0074 pubmed: 25080433 pmcid: 4757910
Martini, C. et al. Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer. Virchows Arch. https://doi.org/10.1007/s00428-023-03643-1 (2023).
Logan, J. M. et al. Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers. Dryad https://doi.org/10.5061/dryad.v9s4mw749 (2024).
Lazniewska, J. et al. Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression. Sci. Rep. 13, 13489 (2023).
doi: 10.1038/s41598-023-40347-7 pubmed: 37596305 pmcid: 10439187
Jhavar, S. et al. Construction of tissue microarrays from prostate needle biopsy specimens. Br. J. Cancer 93, 478–482 (2005).
doi: 10.1038/sj.bjc.6602726 pubmed: 16091762 pmcid: 2361582
Singh, S. S. et al. Feasibility of constructing tissue microarrays from diagnostic prostate biopsies. Prostate 67, 1011–1018 (2007).
doi: 10.1002/pros.20603 pubmed: 17476688
McCarthy, F. et al. An improved method for constructing tissue microarrays from prostate needle biopsy specimens. J. Clin. Pathol. 62, 694–698 (2009).
doi: 10.1136/jcp.2009.065201 pubmed: 19638540
Vogel, U. Overview on Techniques to Construct Tissue Arrays with Special Emphasis on Tissue Microarrays. Microarrays 3, 103–136 (2014).
doi: 10.3390/microarrays3020103 pubmed: 27600339 pmcid: 5003444

Auteurs

Jessica M Logan (JM)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia. jessica.logan@unisa.edu.au.

Carmela Martini (C)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.

Alexandra Sorvina (A)

Centre for Cancer Biology, University of South Australia, North Terrace, Adelaide, SA, 5000, Australia.

Ian R D Johnson (IRD)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.
ORCID: 0000-0001-7875-3510

Robert D Brooks (RD)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.

Maria C Caruso (MC)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.

Chelsea Huzzell (C)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.

Courtney R Moore (CR)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.

Litsa Karageorgos (L)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.

Lisa M Butler (LM)

South Australian ImmunoGENomics Cancer Institute and Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, SA, 5005, Australia.
Solid Tumour Program, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, 5000, Australia.
ORCID: 0000-0003-2698-3220

Prerna Tewari (P)

Department of Histopathology, Trinity College Dublin, D02 PN40, Dublin, Ireland.

Sarita Prabhakaran (S)

Department of Anatomical Pathology, College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.
ORCID: 0000-0003-3252-2519

Shane M Hickey (SM)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.

Sonja Klebe (S)

Department of Anatomical Pathology, College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.

Hemamali Samaratunga (H)

Aquesta Uropathology, The University of Queensland, Brisbane, QLD, 4072, Australia.

Brett Delahunt (B)

Malaghan Institute of Medical Research, Wellington, 6012, New Zealand.

Kim Moretti (K)

Discipline of Surgery, University of Adelaide, Adelaide, SA, 5371, Australia.
Allied Health and Human Performance, University of South Australia, Adelaide, SA, 5005, Australia.
Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, 3800, Australia.

John J O'Leary (JJ)

Department of Histopathology, Trinity College Dublin, D02 PN40, Dublin, Ireland.
ORCID: 0000-0001-7311-9326

Douglas A Brooks (DA)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.

Ben S-Y Ung (BS)

Clinical and Health Sciences, University of South Australia, Bradley Building, City West Campus, North Terrace, Adelaide, SA, 5000, Australia.
Quality Use of Medicines and Pharmacy Research Centre, University of South Australia City East Campus, Frome Rd, Adelaide, SA, 5000, Australia.
ORCID: 0000-0001-7667-3648

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Reinterpretation of prostate cancer pathology...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Reinterpretation of prostate cancer pathology...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Reinterpretation of prostate cancer pathology...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › Syndécanes › Syndécane-1 › Reinterpretation of prostate cancer pathology...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines du transport vésiculaire › Protéines adaptatrices du transport vésiculaire › Reinterpretation of prostate cancer pathology...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › Reinterpretation of prostate cancer pathology...